CELL INTELLIGENCE · 肿瘤细胞治疗研究

IL-15 增强间皮素和 CD70 CAR NK 细胞在 PDAC 中的效力，双靶向未带来额外获益

IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.

双特异性 CAR-T 和 CAR-NK 细胞在双重免疫治疗中的机遇与挑战

Bispecific CAR T and CAR NK cells in dual-threat immunotherapy: opportunities and challenges.

靶向 PD-L1 和 ErbB2（HER2）的双重 CAR-NK 细胞表现出协同 CAR 信号传导并抵抗实体瘤异质性

Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.

同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。

IgG2a 型 4-1BB 激动联合 S100A9 抑制增强多发性骨髓瘤临床前模型中的 T 细胞活化与肿瘤控制

IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma.

这些发现确立了 4-1BB 激动剂的同种型特异性疗效，并支持将 4-1BB 刺激与 TQ 联合作为增强 MM 持久免疫治疗应答的有前景策略。

环磷酰胺-泊马度胺联合方案改变肿瘤细胞分泌组并通过 NK 细胞介导的细胞毒性增强埃罗妥珠单抗的抗骨髓瘤活性

Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediat

现货型双 CAR-iNKT 细胞免疫治疗根除髓内及软脑膜高危 KMT2A 重排白血病

Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.

双靶向 CD155/TIGIT 与 PD-L1/PD-1 免疫检查点增强 NK 细胞介导的髓母细胞瘤细胞毒性

Dual targeting of CD155/TIGIT and PD-L1/PD-1 immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastoma.

这些数据为诊断为 Sonic Hedgehog 亚组和 Group 3 MB 的儿童提出了一种可转化的新型免疫治疗策略。

双靶向胶质母细胞瘤细胞的双特异性杀伤细胞衔接器靶向 EGFR 和 ErbB2（HER2）促进 NKG2D-CAR 工程化 NK 细胞的有效清除

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D

神经母细胞瘤：癌症免疫治疗持续面临的冷锋

Neuroblastoma: an ongoing cold front for cancer immunotherapy.

TCR 工程化的 iNKT 细胞通过双重靶向癌症和抑制性髓系细胞诱导强大的抗肿瘤反应

TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.